Alveolar soft part sarcoma

At Dana-Farber/Children’s Hospital Cancer Center, our care is informed by our research. We have a long and distinguished history of research and innovation in pediatric orthopedics. 

Clinical and basic scientists at Boston Children's Hospital and Dana-Farber Cancer Institute are conducting numerous research studies that will help us better understand and treat soft tissue sarcomas. 

• We are studying angiogenesis inhibitors, substances that may be able to prevent the growth of tumors.
• We are investigating the use of biological therapies, a wide range of substances that may be able to involve the body’s own immune system to fight cancer or lessen harmful side effects of some treatments.
• Researchers are looking into different chemotherapy drugs that may prove effective for children with alveolar soft part sarcoma. 

Children’s is a world leader in opening new avenues of "translational research," bringing laboratory advances to the bedside and doctor's office as quickly as possible. All of our senior medical staff members of the Bone and Soft Tissue Tumors Program participate in clinical research activities. Our program director, Carlos Rodriguez-Galindo, MD, is also the co-director of our new Clinical and Translational Investigation Program, which aims to dramatically improve translational research in pediatric hematology and oncology.

In addition to a variety of clinical trials, Children’s also conducts extensive laboratory research to identify new treatments and improve therapies for benign and malignant bone and soft tissue tumors. 

Learn more about Boston Children's Hospital's groundbreaking research enterprise.